Safe and Affordable Drugs from Canada Act of 2025
The Safe and Affordable Drugs from Canada Act of 2025 would direct the Secretary of Health and Human Services to issue regulations within 180 days allowing individuals to import certain prescription drugs from approved Canadian pharmacies for personal use. The bill is aimed at lowering drug costs by creating a legal pathway for Americans to buy qualifying medications from Canada, subject to several safeguards and eligibility limits.
To qualify, a drug must be purchased from a pharmacy in Canada that the Secretary certifies as approved, dispensed by a licensed Canadian pharmacist, filled with a valid prescription from a U.S.-licensed physician, and limited to a 90-day supply for personal use. The imported drug must also match an FDA-approved U.S. drug in active ingredient, route of administration, dosage form, and strength. The bill excludes a wide range of products, including controlled substances, biologics, infused and injectable drugs, many biotechnology-derived products, refrigerated drugs, and photoreactive drugs.
The bill would amend the Federal Food, Drug, and Cosmetic Act by adding a new section governing individual importation from Canada. It also requires FDA to publish a public list of approved Canadian pharmacies and sets certification criteria for those pharmacies, including a minimum five-year existence, compliance with Canadian provincial pharmacy rules, quality assurance programs, testing through approved laboratories, grievance procedures, and a ban on reselling drugs sourced from online pharmacies outside Canada.
The available context shows no recorded committee debate or votes, so the overall sentiment is inferred from the bipartisan sponsorship and the bill’s consumer-cost framing. The sponsors include senators from both parties, suggesting broad interest in addressing prescription drug affordability. The bill’s design reflects a pro-access, pro-safety approach rather than an unrestricted importation model.
The main points of contention are likely to center on drug safety, regulatory oversight, and the impact on domestic pharmaceutical markets. Supporters would likely emphasize lower prices and expanded access for patients, while critics may raise concerns about counterfeit or diverted drugs, enforcement challenges, and whether importing medicines from abroad could undermine FDA oversight or U.S. drug supply chains.
The bill would amend chapter VIII of the Federal Food, Drug, and Cosmetic Act by creating a new federal importation framework for certain prescription drugs purchased by individuals from approved Canadian pharmacies. It would require FDA/HHS rulemaking, establish a certification and publication process for approved pharmacies, and create new statutory exclusions and compliance standards that would affect patients, pharmacies, regulators, and potentially prescription drug distribution practices.
There is no committee transcript or vote record available, so sentiment cannot be measured directly from debate or roll call history. Based on the bill text and bipartisan sponsorship, the measure appears to have generally favorable framing around affordability and access to medications, with an emphasis on safety controls to address likely regulatory concerns.
Likely contention would focus on whether the importation pathway is safe, enforceable, and compatible with FDA oversight. Supporters are likely to prioritize lower prescription drug costs and access for patients, while opponents or skeptics may worry about counterfeit drugs, quality control, diversion, and the administrative burden of certifying Canadian pharmacies and policing compliance. The bill’s exclusions for biologics, injectables, refrigerated drugs, and biotechnology-derived products suggest an effort to limit risk, but those limits may also be viewed as narrowing the bill’s practical effect.